Breast Cancer | Specialty

Extended Adjuvant Therapy for HER2-Positive Breast Cancer

June 16th 2017

Adjuvant Therapy for HER2-Driven Breast Cancer

June 16th 2017

PI3K Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

Sequencing in Hormone-Driven Metastatic Breast Cancer

June 16th 2017

Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer

June 15th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

June 6th 2017

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer

June 6th 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Dr. Hayes on the Future of Biomarkers for Breast Cancer

June 6th 2017

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Adjuvant Pertuzumab May Help Some Early Breast Cancer Patients

June 5th 2017

The addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer slightly improved the rate of recurrence overall but had a greater benefit for individuals with higher-risk disease, particularly as more time elapsed, according to early results from the phase III APHINITY trial.

Pembrolizumab Again Demonstrates Durable Activity in TNBC

June 5th 2017

Pembrolizumab (Keytruda) showed durable antitumor activity in patients with heavily pretreated metastatic triple-negative breast cancer (TNBC), according to findings from cohort A of the phase II KEYNOTE-086 trial presented at the 2017 ASCO Annual Meeting.

Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2- Breast Cancer

June 5th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.

Olaparib Extends PFS in Phase III BRCA+ Breast Cancer Trial

June 4th 2017

The PARP inhibitor olaparib (Lynparza) reduce the risk of disease progression by 42% versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Abemaciclib Extends PFS in Phase III Breast Cancer Trial

June 4th 2017

Adding the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression or death by 45% versus fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer, according to findings presented at the 2017 ASCO Annual Meeting.

Pregnancy Does Not Increase Recurrence Risk of Early-Stage, ER-Positive Breast Cancer

June 3rd 2017

Women who have had early breast cancer, along with their doctors, often worry that pregnancy could cause disease recurrence. But according to the results of a new study, that’s not the case.

Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention

June 3rd 2017

Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.